These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 36200701)

  • 1. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.
    Carlin AF; Clark AE; Chaillon A; Garretson AF; Bray W; Porrachia M; Santos AT; Rana TM; Smith DM
    Clin Infect Dis; 2023 Feb; 76(3):e530-e532. PubMed ID: 35723411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
    Panza F; Fiorino F; Pastore G; Fiaschi L; Tumbarello M; Medaglini D; Ciabattini A; Montagnani F; Fabbiani M
    Microorganisms; 2023 Oct; 11(10):. PubMed ID: 37894265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
    Qi T; Jin Y; Wang H; Liao Y; Liu T; Mao E; Li F; Li Y; Fan X; Ling Y
    J Med Virol; 2023 Feb; 95(2):e28497. PubMed ID: 36651302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    Lai CC; Hsueh PR
    J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
    Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
    JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
    Yan M; Xie M; Zhu S; Li H; Li S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
    Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
    Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
    Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
    medRxiv; 2023 Jun; ():. PubMed ID: 37425934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals.
    Smith-Jeffcoat SE; Biddle JE; Talbot HK; Morrissey KG; Stockwell MS; Maldonado Y; McLean HQ; Ellingson KD; Bowman NM; Asturias E; Mellis AM; Johnson S; Kirking HL; Rolfes MAR; Olivo V; Merrill L; Battan-Wraith S; Sano E; McLaren SH; Vargas CY; Goodman S; Sarnquist CC; Govindaranjan P; Petrie JG; Belongia EA; Ledezma K; Pryor K; Lutrick K; Bullock A; Yang A; Haehnel Q; Rao S; Zhu Y; Schmitz J; Hart K; Grijalva CG; Salvatore PP
    Clin Infect Dis; 2024 May; 78(5):1175-1184. PubMed ID: 37963102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
    Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
    J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.